Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for posttraumatic stress disorder (PTSD). For more information, please visit www.recoverystudy.com or www.clinicaltrials.gov (NCT03841773).
Seth Lederman is a physician, scientist and founder and executive officer of innovative biopharmaceuticals companies. Prior to founding Tonix, among the companies Dr. Lederman founded was Targent Pharmaceuticals, which developed late-stage oncology drugs, including pure-isomer levofolinic acid (levoleucovorin). Targent’s assets were sold to Spectrum Pharmaceuticals, which marketed levoleucovorin as Fusilev® for advanced colorectal cancer, where it gained significant market acceptance.
Dr. Lederman served as an Associate Professor at Columbia University from 1996 until April 13, 2017. He joined the faculty of Columbia University's College of Physicians and Surgeons in 1985, became Assistant Professor of Medicine in 1988, and Associate Professor with tenure in 1996 and Director of the Laboratory of Molecular Immunology in 1997. From 1988 to 2002, Dr. Lederman directed basic science research at Columbia in molecular immunology, infectious diseases and the development of therapeutics for autoimmune diseases. Dr. Lederman is author of numerous scientific articles, and inventor of technologies recognized by a number of issued patents. His fundamental work on the CD40-Ligand (CD154) elucidated the molecular basis of T cell helper function and has led to the development of therapeutic candidates for autoimmune diseases and organ transplant rejection in collaboration with Biogen and UCB. The successful defense of his CD154 patents has led to important precedents in defining the relationship of therapeutics and molecular targets. In collaboration with Prof. David Baltimore (then at Rockefeller University and later MIT), Dr. Lederman identified and functionally characterized the CD40 signaling molecule, TRAF-3. His early work on HIV contributed to the understanding of how the V3 loop of HIV gp120 was involved in fusion with CD4 cell membranes, an early and essential event in viral entry and infection. In addition to his research, Dr. Lederman served as attending physician in the Edward Daniels Arthritis and Autoimmunity Clinic on the Medical Service at Columbia Presbyterian Hospital from 1988-1996.
Dr. Lederman represented U.S. Biotechnology at a Beijing Summit in September 2015 with China’s President Xi Jinping. The Summit was organized by the U.S. Chamber of Commerce and involved a delegation of U.S. CEOs, former U.S. Cabinet officials and leading academic experts.
Dr. Lederman earned an AB from Princeton in Chemistry cum laude in 1979 and an MD from Columbia University's College of Physicians and Surgeons in 1983. Dr. Lederman trained in internal medicine and rheumatology at Columbia's Presbyterian Hospital. He was an NIH Physician-Scientist 1985-1990 at Columbia.
Margaret Smith Bell was a Vice President at Standard Life Investments where she was a portfolio manager and health care equity analyst. Previously, Ms. Bell was a Managing Director at Putnam Investments, and served as a senior health care analyst and a portfolio manager of the Putnam Health Sciences Trust. Ms. Bell's healthcare experience also includes equity research positions with State Street Research and Alex. Brown & Sons, Inc. Ms. Bell is a past member of the Board of Overseers at Beth Israel Deaconess Medical Center. Ms. Bell holds a B.A. from Wesleyan University and an M.B.A. from the Wharton School at the University of Pennsylvania.
Dr. Goodman is a psychiatrist and scientist entrepreneur. Dr. Goodman was co-founder and CEO of PsychoGenics, a leading preclinical neuropharmacology company that combines its in vivo behavioral expertise with robotics, computer vision, and bio/cheminformatics to evaluate drug candidates for utility across the spectrum of neuropsychiatric disease indications. Using its unique technology platform, PsychoGenics identifies new therapeutic potentials for novel, discontinued and early stage compounds. Dr. Goodman was also co-founder and President of Resolvyx Pharmaceuticals, a biopharmaceutical company dedicated to the discovery, development and commercialization of resolvins, a novel class of therapies to treat inflammatory diseases. Dr. Goodman's ongoing research interests span a broad spectrum, from the design and development of novel small molecule compounds for neuropsychiatric and inflammatory diseases to the repurposing of existing drugs for new neuropsychiatric indications. In addition to his scientific interests, Dr. Goodman is a practicing physician with a private psychiatry and psychopharmacology practice in New York and Greenwich, CT, where he treats patients with cognitive, mood, and anxiety disorders. Dr. Goodman also maintains an academic appointment as a clinical assistant professor in the Psychiatry Department at Cornell University Medical College, where he teaches medical students, residents and fellows.
He is a graduate of Yale College, Cambridge University, which he attended as a Churchill Fellow, Harvard Medical School, and Columbia Business School.
General Grange is currently Chief Executive Officer of Pharm-Olam International, Ltd. Prior to joining Pharm-Olam, he was President of Osprey Global Solutions, LLC “OGS”, a Service Disabled Veterans Organization. Gen. Grange served as the Chief Executive Officer of Pharmaceutical Product Development, Inc. “PPDI”, where he oversaw clinical and laboratory operations. Prior to PPDI he served in the McCormick Tribune Foundation for 10 years, most recently as Chief Executive Officer and President, where he also oversaw the support of Veteran Programs. Gen. Grange served 30 years in the U.S. Army as a Ranger, Green Beret, Aviator, Infantryman and a member of special operating units. At the Pentagon, he was Director of Army Current Operations, Readiness, and Mobilization. Gen. Grange commanded the Ranger Regiment and the First Infantry Division (the Big Red One). He holds a master’s degree in Public Service from Western Kentucky University.
Dr. Olukotun is the Chief Executive Officer of CR Strategies, LLC, which consults on clinical trial design and FDA strategy for pharmaceutical product development. He is the former Chief Executive Officer of EpiGen Pharmaceuticals, Inc. and the former Vice Chairman and Chief Executive Officer of CardioVax, Inc. He is also co-founder of VIA Pharmaceuticals and served as the company's Chief Medical Officer. Dr. Olukotun has 30 years of experience in clinical research and drug development in the pharmaceutical industry. Before CardioVax and VIA, he was Chief Medical Officer of Esperion Therapeutics, Inc., a cardiovascular drug development company, until its acquisition by Pfizer in 2004. From 1996 to 2000, Dr. Olukotun was Vice President of Medical and Regulatory Affairs and Chief Medical Officer of Mallinckrodt Inc. Prior to joining Mallinckrodt, Dr. Olukotun spent 14 years at Bristol-Myers Squibb Company, including time at Squibb prior to the merger with Bristol Myers in 1989. At Squibb, Dr. Olukotun was part of the team that won FDA approval for two revolutionary drugs: Capoten® (captopril) and Pravachol® (pravastatin). Capoten was the first rationally designed drug and the first angiotensin converting enzyme (ACE) inhibitor to win FDA approval. Pravachol was the second statin to win U.S. FDA approval. Both became blockbusters and are still widely prescribed today as generics. The inventor of pravastatin, Professor Akira Endo won the Lasker-DeBakey Clinical Medical Research Award and the inventors of captopril, David Cushman and Miguel Ondetti won Albert Lasker Clinical Medical Research Award. Dr. Olukotun received his medical degree from Albert Einstein College of Medicine and obtained a Master of Public Health degree from Harvard School of Public Health. Dr. Olukotun is a Board-Certified cardiologist and a Fellow of the American College of Cardiology as well as the American Heart Association.
Mr. Rhodes is the President and CEO of the New York State Energy Research and Development Authority (NYSERDA), a public benefit corporation which offers information and analysis, technical expertise and funding to help New Yorkers increase energy efficiency and reduce reliance on fossil fuels. Mr. Rhodes works with public and private partners to expand investment and innovation in energy to drive New York's clean energy economy and stimulate economic activity. Mr. Rhodes is a former partner at Booz Allen Hamilton (1987-2002) where he led significant work in strategy and commercial operations globally for clients in biotech and pharmaceuticals. He had a particular focus on business optimization, including clinical development strategies for new and existing molecules, market repositioning and commercial operations for established drugs, and business development strategies to enhance drug portfolios and pipelines. Recently Mr. Rhodes served as Senior Advisor to Good Energies (2007-2010), a private investment firm focused on renewable energy and energy efficiency, where he developed strategy, supported portfolio companies and served on the management team. Mr. Rhodes serves on the board of several non-profit organizations, including the Hospital for Joint Diseases, New York, and the American Federation for Aging Research, New York. Mr. Rhodes is a graduate of Princeton University (1979) and the Yale School of Management (1987).
Mr. Treco is a Managing Partner at First Chicago Advisors, Inc., a boutique financial advisory firm where he advises executives and boards of directors of a wide range of companies, from global, large-cap companies to emerging companies. During his career he has worked with various biotechnology companies. For the past decade, he has been involved with start-up companies affiliated with Dartmouth Hitchcock Medical Center in Hanover, NH developing intellectual properties, a number of which have been sold and licensed to larger, publicly-traded pharmaceutical companies. Prior to joining First Chicago Advisors, Mr. Treco was an investment banker with Gleacher & Company that previously operated an investment banking business, providing corporate and institutional clients with strategic and financial advisory services. Mr. Treco held various positions of increasing responsibility at Salomon Brothers/Citigroup, where he used his extensive experience in the global capital markets to advise a wide range of clients. Mr. Treco earned a B.A. from Yale University and an M.B.A. from the Stanford University Graduate School of Business.